Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003099 · ClinicalTrials.gov registry record · Phase 2
Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00003099: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00003099 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003099, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide and tamoxifen before surgery may be an effective way to prevent the recurrence of or further development of breast cancer. PURPOSE: Randomized phase II trial to study the effectiveness of fenretinide and tamoxifen given before surgery in treating women with breast cancer.
Interventions
- OTHER Placebo
- DRUG Fenretinide
- DRUG Tamoxifen Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 1996-05 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003099
The ClinicalTrials.gov registry entry for NCT00003099 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00003099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003099 about?
NCT00003099 is a clinical study titled "Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide and tamoxifen before surgery may be an effective way to prevent the recurrence of or further development of breast cancer. PURPOSE: Randomized phase II tr...
What is the current status of trial NCT00003099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 1996-05. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00003099?
The interventions under investigation include: Placebo (OTHER), Fenretinide (DRUG), Tamoxifen Citrate (DRUG).
Who is sponsoring clinical trial NCT00003099?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.